肾透明细胞癌
癌症研究
转移
自分泌信号
生物
福克斯A2
辅活化剂
旁分泌信号
转录因子
细胞
车站3
上皮-间质转换
医学
细胞生长
细胞迁移
下调和上调
肿瘤进展
T细胞
信号转导
癌变
清除单元格
免疫学
癌症
免疫疗法
转化生长因子β
PD-L1
小发夹RNA
内科学
作者
Cong Huang,Rui Rui,Heng Guo,Anbang He,Wenzhi Gao,Jian Fan,Cuijian Zhang,Yanqing Gong,Liqun Zhou,Xuesong Li,Shiming He
摘要
Despite recent therapeutic advances, the prognosis of patients with metastatic clear cell renal cell carcinoma (ccRCC) remains poor, and the molecular mechanisms driving metastasis are not fully understood. Herein, we identify forkhead box transcription factor A2 (FOXA2) as a key regulator of ccRCC metastasis. FOXA2 expression is elevated in metastatic ccRCC and correlates with adverse clinical outcomes. Functional assays show that FOXA2 enhances ccRCC cell invasion and metastasis both in vitro and in vivo. Mechanistically, FOXA2 recruits the histone acetyltransferase HAT1 as a transcriptional coactivator to upregulate growth differentiation factor 15 (GDF15) expression, which in turn activates GFRAL/RET-mediated STAT3 signaling and the epithelial-to-mesenchymal transition (EMT), thereby driving metastasis through both autocrine and paracrine pathways. Moreover, tumor cell-secreted GDF15 facilitates CD8+ T cell exhaustion within the tumor microenvironment, contributing to immune evasion and resistance to anti-PD-1 therapy. Importantly, pharmacologic inhibition of this pathway using either the GDF15-neutralizing antibody ponsegromab or the RET inhibitor pralsetinib markedly impairs FOXA2-driven metastasis and synergizes with anti-PD-1 therapy. Together, our findings delineate a FOXA2-GDF15-STAT3 signaling axis that orchestrates metastatic progression and immune suppression in ccRCC and suggest promising therapeutic strategies for patients with advanced disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI